I would temper your expectations regarding Dr. Hampel's presentation--and the perceived effect it may have on near term SP. I really don't think this will move the needle. Perhaps it may garner some attention to the company that would otherwise not be there, but I don't think this will have any material impact near term.
I am VERY excited about Rett, and am grateful that DM persevered to finally gain the FDA's approval--albeit with a limited sized trial initially.
We seem to be heading in a positive direction. Now we just need to get these trials fully enrolled and begin dosing. Easier said than done, but time is money.